ATO, a GLI antagonist, blocks GLI protein function (111) and when combined with the SMO inhibitor, itraconazole, it effectively overcomes the resistance to SMO inhibition seen in models of medulloblastoma and BCC (112). Here, SMO is linked to medulloblastoma.